Alopecia Areata Treatment in Ukraine

The hair follicle is one of the few parts of the body that the immune system normally leaves alone: the bulb is protected by what is known as immune privilege. In alopecia areata this protection breaks down, and T lymphocytes cluster around follicles in their growth phase and force them into premature dormancy; under the microscope this cluster is described as a "swarm of bees".

The key point: the follicle does not die. It shrinks and goes dormant, but its stem cell zone stays intact and the follicle opening on the skin is preserved. That is why hair can grow back even on an area that has been bare for several years, and this is exactly what sets alopecia areata apart from scarring forms, in which the opening is permanently replaced by scar tissue.

The condition can take different forms. The classic form is one or more round patches of smooth skin; ophiasis is a band of hair loss along the lower edge of the back of the head and above the ears; total alopecia means losing all the hair on the head, and universal alopecia means losing the eyebrows, eyelashes and body hair as well. The beard can also be affected, and the nails often develop tiny pinpoint pits, like the surface of a thimble.

The condition rarely comes alone. Autoimmune thyroiditis, vitiligo, atopic dermatitis and asthma occur alongside it more often than in the general population. Its course is unpredictable: a first single patch regrows on its own within a year in a considerable share of patients, yet most people have relapses during their lifetime. The outlook is worse with ophiasis, onset in childhood, nail involvement and loss of more than half the hair.

MediUkraine is a service that finds and coordinates treatment; it is not a clinic. We choose the clinic and a dermatologist experienced in autoimmune hair loss, arrange the appointment date and support you throughout, including if you are travelling from abroad. Diagnosis and treatment decisions are made by the doctor after an in-person examination.

Treatment is chosen based on three factors: how much area is affected, how fast the condition is progressing and the patient's age. The working threshold is 50% of the scalp: below it, topical treatments and injections into the patches are used; above it, local methods cannot keep up with the disease. Most injectable and systemic options are not suitable for children.

Topical corticosteroids are first-line treatment for limited forms and almost the only option for young children. Potent preparations in lotion, foam or ointment form are used in courses with breaks: the evidence is moderate, but the method is simple. The price of uncontrolled use is skin thinning and steroid folliculitis.

Intralesional triamcinolone injections are the main treatment for adults with limited patches. The drug is diluted to 2.5–10 mg/ml and injected with a fine needle at several points across the patch; a session takes 10–20 minutes and is repeated every 4–6 weeks. Regrowth is achieved in about two thirds of patients, with the first fine hairs appearing after 4–6 weeks. The most common side effect is a temporary dent in the skin at the injection site.

Injections are not given all over the head "just in case". If new patches keep appearing within a few weeks, local treatment no longer makes sense, and a short course of systemic glucocorticoids is considered. It can stop a wave of hair loss, but the effect often lasts only while the medicine is taken, and long-term steroid treatment is not justified here.

Topical immunotherapy with diphencyprone is used for extensive forms and works paradoxically: a substance that causes controlled contact dermatitis is deliberately applied to the skin, and this reaction diverts the immune attack away from the follicles. Applications then continue weekly at the clinic and are washed off after 24–48 hours. Results vary widely: in limited forms, regrowth is reported in most patients, and in total and universal forms in about one in six, with relapse in a third. In Ukraine the method is available at only a handful of centres.

Janus kinase (JAK) inhibitors have changed the treatment of severe forms. Baricitinib and ritlecitinib are approved by US and EU regulators for severe alopecia areata, and deuruxolitinib was approved later. They block the signalling pathway immune cells use to communicate. In the registration trials, roughly 35–40% of patients reached a point where no more than a fifth of the scalp remained affected; this takes six months or more.

The limitations are serious, and the clinic should explain them before the first prescription. The medicine has to be taken continuously: once it is stopped, hair loss usually returns. Laboratory monitoring is required: blood counts, liver tests and lipids, plus screening for tuberculosis and hepatitis before starting; there are warnings about infections and thrombosis. Add the cost of treatment and limited availability in Ukraine: not all of these medicines are on the market, so check their status at the consultation.

Other methods play a supporting role. Minoxidil does not stop alopecia areata on its own because it does not affect the immune attack, but it is added to the main treatment. Scalp mesotherapy has no standard formulation or protocol: reviews describe small, unblinded studies, and there is not enough data to recommend it. PRP has been studied less here than in inherited thinning, and vitamins (without a confirmed deficiency) do not affect the course of the disease.

Hair transplantation is not performed in active alopecia areata. The reason is biology, not technique: a transplanted follicle comes under the same immune attack and falls out just like the native one, and the donor area is used up for nothing. Besides, your own follicles in the patch are alive and may regrow on their own. A transplant is discussed, if at all, only after years of stable remission.

The psychological side of the condition is as real as the medical one. Losing eyebrows and eyelashes changes the face more than a patch hidden under the hair, and in children the disease affects school life; anxiety and depression are more common in people with this condition. That is why the plan also covers practical matters: a wig or hair system, eyebrow make-up, protecting the eyes without eyelashes and support from a psychologist.

A word on the advice to "wait and it will go away". A single small patch does often regrow within a year without treatment, and watchful waiting is a legitimate approach here. But waiting is risky if there are several patches, ophiasis has appeared, the nails are affected or the area is growing quickly: the longer treatment is delayed, the poorer the response. A decision to watch and wait is made after an examination and with a follow-up date.

The first thing to appear in a patch is not hair but colourless fine down. After intralesional injections it usually becomes visible after 4–6 weeks: at first thin and pale, it gradually thickens and gains colour. The area may look grey for a long time; this is a normal stage, not a side effect.

For local treatment, a reasonable time to assess results is three months. If there is no regrowth at all in the patch after three or four injection sessions, the treatment is changed rather than continued out of habit. Prolonging an ineffective course is especially costly with this condition: meanwhile, the affected area may grow.

Systemic treatment works on a different timescale. JAK inhibitors are assessed at weeks 24–36, and in some patients the full response takes closer to a year, so stopping after two months "because it isn't working" is a common mistake. The interim visits are needed for laboratory monitoring, not just to report on progress.

Remission does not mean the disease is over. Alopecia areata comes in waves, and a new patch a year or five years later does not prove that the previous treatment was pointless. It is better to know this in advance than to experience a relapse as a personal failure.

Monitoring is based on figures and images: repeat trichoscopy of the same areas, assessment of the affected area on the SALT scale, and photos taken under the same lighting. "It seems to be better" is not enough: hair grows back too slowly for the eye to catch the change between visits.

If you live abroad, part of the monitoring can conveniently be done remotely. You keep the report, the images and the treatment record, a local dermatologist can continue the follow-up, and if needed MediUkraine arranges a video consultation with the same doctor or your next in-person visit.